Autonomix Medical, Inc.

AMIX

Nasdaq; healthcare; SIC 3841, Surgical & Medical Instruments & Apparatus; CIK 0001617867


None

No letter

3 of 13 inputs computable; 7 are required, with a score in every sleeve


Scoreboard	
Reliability	0.76 AUC filers with under $12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025
Peer failure rate	0.60% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	under $12.5M assets total assets $7.6M
Standard universe	outside revenue above $1M and assets above $10M
Warnings	thin data, degenerate inputs not computable: dilution, distress, fortress balance sheet
Inputs computable	3 of 13
Graded from	filings received through Jun 15, 2026 155 days before the rescan; latest periodic filing 10-Q received Nov 10, 2026
Last close	$0.97 2026-11-16; market equity $2.0M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received May 27, 2026

We are a development-stage medical device company focused on advancing technologies for sensing and treating disorders of the nervous system. Our platform is designed to integrate high-sensitivity neural signal detection with targeted radiofrequency ("RF") ablation, enabling a "sense, treat, verify" approach intended to improve the precision and consistency of nerve-targeted therapies. The technology we have developed consists of a catheter-based system incorporating a proprietary microchip-enabled sensing architecture designed to detect low-amplitude neural signals from within the vascular system.

The thirteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 6.8						
Gross profitability	not computable	32.8%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.6%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

one or more required annual facts are missing					
Accruals ratio	(50.9%)	(6.7%)	6.8	756	2026-03-31
Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 0					
Solvency, sleeve percentile 63.4					
Altman Z double-prime	(35.14)	0.31	84.9	705	2026-03-31
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(3.61x)			
one or more required annual facts are missing					
Current ratio	4.45x	2.68x	41.8	781	2026-03-31
Growth and financing					
Revenue growth, three-year compound	not computable	9.6%			
four annual observations are required; found 3					
Free cash flow growth, three-year compound	not computable	11.1%			
four consecutive annual FCF observations are required; found 2					
Reinvestment rate	not computable	33.9%			
NOPAT must exceed $100,000					
Asset growth, three years	not computable	3.2%			
four annual observations are required; found 3					
Net share issuance, one year	not computable	1.6%			
prior share count is 20 days earlier					

Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Thin data	3 of 13 grade factors are computable; minimum is 7
Degenerate inputs	latest revenue or assets are at or below the $100,000 validity floor

What the price implies

at the 2026-11-16 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(82.3%)	(1.7%)	4
Distance from 52-week high	(95.4%)	(31.5%)	2
EBIT to enterprise value	not computable	0.5%	
Free cash flow yield	(546.4%)	0.5%	1
Book value to price	3.09	0.28	96
Sales to price	0.00	0.36	0
Composite equity issuance, five years	not computable	13.2%	
Relative strength against the sector, log excess return	(1.90)	(0.19)	4
Twelve-month failure probability, CHS model	not computable	0.06%	

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2026-03-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail

Cash, filings, liquidity

Cash and equivalents	$7.7M
Operating cash flow, four quarters	-$12.0M
Months of runway	7.7
Days since last periodic filing	7 (10-Q received Nov 10, 2026)
Median daily dollar volume, 63 sessions	$284,458

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$16.7M	2026-03-31	2026-05-27	10-K	26-018573
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$12.3M	2026-03-31	2026-05-27	10-K	26-018573
3	assets	us-gaap:Assets	$7.6M	2026-03-31	2026-05-27	10-K	26-018573
4	assets	us-gaap:Assets	$9.8M	2025-03-31	2026-05-27	10-K	26-018573
5	current assets	us-gaap:AssetsCurrent	$7.6M	2026-03-31	2026-05-27	10-K	26-018573
6	current liabilities	us-gaap:LiabilitiesCurrent	$1.7M	2026-03-31	2026-05-27	10-K	26-018573
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$67.1M	2026-03-31	2026-05-27	10-K	26-018573
8	operating income	us-gaap:OperatingIncomeLoss	-$17.0M	2026-03-31	2026-05-27	10-K	26-018573
9	book equity	us-gaap:StockholdersEquity	$5.9M	2026-03-31	2026-05-27	10-K	26-018573
10	liabilities	us-gaap:Liabilities	$1.7M	2026-03-31	2026-05-27	10-K	26-018573
11	revenue	us-gaap:Revenues	$0	2026-03-31	2026-05-27	10-K	26-018573
12	revenue	us-gaap:Revenues	$0	2025-03-31	2026-05-27	10-K	26-018573
13	revenue	us-gaap:Revenues	$0	2024-03-31	2025-05-29	10-K	25-018831
14	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$10,000	2026-03-31	2026-05-27	10-K	26-018573
15	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$12,000	2026-03-31	2026-05-27	10-K	26-018573
16	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$16.7M	2026-03-31	2026-05-27	10-K	26-018573
17	income tax	us-gaap:IncomeTaxExpenseBenefit	$0	2026-03-31	2026-05-27	10-K	26-018573
18	current assets	us-gaap:AssetsCurrent	$9.6M	2025-03-31	2026-05-27	10-K	26-018573
19	current liabilities	us-gaap:LiabilitiesCurrent	$1.7M	2025-03-31	2026-05-27	10-K	26-018573
20	assets	us-gaap:Assets	$9.4M	2024-03-31	2025-05-29	10-K	25-018831
21	shares outstanding	dei:EntityCommonStockSharesOutstanding	11,409,344	2026-06-10	2026-06-15	10-K/A	26-020686
22	shares outstanding	dei:EntityCommonStockSharesOutstanding	11,409,344	2026-05-21	2026-05-27	10-K	26-018573

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.